OPKO HEALTH INC. - COMMON STOCK

OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

08 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

23 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

16 Feb 2023 10:41:10 By Nasdaq GlobeNewswire

OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results

08 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022

01 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

OPKO Health Announces Leadership Changes for BioReference Laboratories

16 Aug 2022 15:29:00 By Nasdaq GlobeNewswire

OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results

04 Aug 2022 15:05:07 By Nasdaq GlobeNewswire

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

25 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

OPKO Health to Present at the 2022 Jefferies Healthcare Conference

02 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results

09 May 2022 15:05:01 By Nasdaq GlobeNewswire

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

09 May 2022 08:23:34 By Nasdaq GlobeNewswire

OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

05 May 2022 15:05:02 By Nasdaq GlobeNewswire

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

24 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

17 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

03 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

20 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

23 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

08 Dec 2021 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Announces the Passing of Director Dr. Richard Lerner

06 Dec 2021 07:00:02 By Nasdaq GlobeNewswire